Literature DB >> 15794715

Toxicity of the topoisomerase II inhibitors.

Karen Seiter1.   

Abstract

Topoisomerase II inhibitors represent a broad class of antineoplastic agents with a wide spectrum of activity against malignancies. Topoisomerase II inhibitors include the anthracyclines, mitoxantrone and epipodophyllotoxins. Short-term toxicity includes myelosuppression and gastrointestinal toxicity. Long-term survivors are at risk of cardiac toxicity and secondary leukaemia. This article discusses these toxicities in detail, including administration of these agents to patients with hepatic and/or renal insufficiency, and the need for dose adjustments in selected patient populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794715     DOI: 10.1517/14740338.4.2.219

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  27 in total

1.  [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

Authors:  C Meyer; N Ansorge; I Siglienti; S Salmen; A Stroet; H Nückel; U Dührsen; P R Ritter; W E Schmidt; R Gold; A Chan
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

2.  Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.

Authors:  Wei Zhang; Yinan Zheng; Lifang Hou
Journal:  Curr Genet Med Rep       Date:  2013-09-01

3.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

4.  Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.

Authors:  Theodore S Johnson; Catherine E Terrell; Scott H Millen; Jonathan D Katz; David A Hildeman; Michael B Jordan
Journal:  J Immunol       Date:  2013-11-20       Impact factor: 5.422

5.  Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.

Authors:  Stefanie C Huelsenbeck; Anne Schorr; Wynand P Roos; Johannes Huelsenbeck; Christian Henninger; Bernd Kaina; Gerhard Fritz
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

6.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Authors:  Shai J White; Laura M Kasman; Margaret M Kelly; Ping Lu; Laura Spruill; Paul J McDermott; Christina Voelkel-Johnson
Journal:  Free Radic Biol Med       Date:  2007-07-03       Impact factor: 7.376

8.  Etoposide attenuates zymosan-induced shock in mice.

Authors:  M Remichkova; M Yordanov; P Dimitrova
Journal:  Inflammation       Date:  2007-10-09       Impact factor: 4.092

Review 9.  Pediatric oncology.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Curr Opin Chem Biol       Date:  2007-07-24       Impact factor: 8.822

10.  Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.

Authors:  Vera Marisa Costa; João Paulo Capela; Joana R Sousa; Rute P Eleutério; Patrícia R S Rodrigues; José Luís Dores-Sousa; Rui A Carvalho; Maria Lourdes Bastos; José Alberto Duarte; Fernando Remião; M Gabriela Almeida; Kurt J Varner; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-09-07       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.